We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.55 | 9.30 | 9.80 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.40 | 88.61M |
From Apr 2019 to Apr 2024
TIDMSCLP
RNS Number : 5744L
Scancell Holdings Plc
01 May 2020
01 May 2020
Scancell Holdings plc
("Scancell" or the "Company")
Director reduced salaries and award of share options
Scancell (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer announces that in recognition of the impact of the COVID-19 crisis and to help fund the initial research work to develop a vaccine for COVID-19 the members of the Company's Senior Management Team have agreed to a temporary 25% reduction in salaries with effect from 1(st) May 2020. None of Scancell's other employees will be affected.
Scancell announces that on 30 April 2020 it has granted 1,000,000 share options to acquire ordinary shares of 0.1 pence each in the capital of the Company ("Ordinary Shares") to each of the members of its Senior Management Team (Dr John Chiplin, Dr Cliff Holloway, Professor Lindy Durrant, Dr Sally Adams, Dr Richard Goodfellow and Mr Keith Green).
The Options have an exercise price of 8.15 pence each and will vest twelve months from the date of Grant.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Hot Features
Premium
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr John Chiplin
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Cliff Holloway
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Professor Lindy Durrant
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Sally Adams
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Dr Richard Goodfellow
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Keith Green
================================ =====================================
2 Reason for the notification
=======================================================================
a) Position/status PDMR
================================ =====================================
b) Initial notification/Amendment Initial notification
================================ =====================================
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
=======================================================================
a) Name Scancell Holdings plc
================================ =====================================
b) LEI 2138008RXEG856SNP666
================================ =====================================
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
=======================================================================
a) Description of Options to acquire Ordinary Shares
the financial instrument,
type of instrument
================================ =====================================
b) Nature of the transaction Grant of options to acquire Ordinary
Shares
================================ =====================================
c) Price(s) and volume(s) Price(s) Volume(s)
8.15 pence 1,000,000
----------
================================ =====================================
d) Aggregated information
- Aggregated volume N/A (Single transaction)
- Price
================================ =====================================
e) Date of the transaction 30 April 2020
================================ =====================================
f) Place of the transaction Outside a trading venue
================================ =====================================
- ENDS -
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).
For more information, please contact:
+44 (0)20 3727
Scancell Holdings plc 1000
Dr John Chiplin, Chairman
Dr Cliff Holloway, CEO
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0) 20 7886
and Joint Broker) 2500
Corporate Finance: Freddy Crossley, Emma
Earl
Corporate Broking: James Stearns
+44 (0)20 3727
FTI Consulting 1000
Simon Conway
Natalie Garland-Collins
Notes for Editors
About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.
ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.
-- SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.
-- SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.
Moditope(R) represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope(R) alone, or in combination with other agents, has the potential to treat a wide variety of cancers.
-- Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.
AvidiMab(TM) is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.
In response to the COVID-19 pandemic, Scancell has turned its clinical expertise in cancer to produce a simple, safe, cost-effective and scalable vaccine to induce both durable T cell responses and virus neutralising antibodies against SARS-Cov-2, the virus that causes COVID-19. The Company believes this combined T cell and antibody approach should give more potent and long-lasting responses, ultimately leading to better protection.
For further details, please see our website: www.scancell.co.uk
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHDZGFDNGFGGZM
(END) Dow Jones Newswires
May 01, 2020 02:00 ET (06:00 GMT)
1 Year Scancell Chart |
1 Month Scancell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
